Summary & Overview
HCPCS J1163: Injection, diltiazem hydrochloride, 0.5 mg
HCPCS Level II code J1163 denotes a 0.5 mg injection of diltiazem hydrochloride, a short-acting intravenous formulation of a calcium channel blocker used in acute cardiovascular care. Nationally, clear coding for injectable cardiac medications matters for accurate claims processing, hospital billing, and drug utilization tracking, especially in emergency and outpatient infusion settings. This code identifies the specific drug unit administered and supports differentiation from oral or continuous infusion formulations.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on clinical context for injectable diltiazem, typical sites of service where it is administered, and common operational considerations for billing and coding workflows. The publication outlines benchmarks and reimbursement context where available, highlights relevant policy or coding updates that affect injectable drug reporting, and provides practical guidance on documenting service lines and units for claims adjudication.
The report is designed for billing managers, revenue cycle professionals, clinical pharmacists, and policy analysts who need a national-level reference for HCPCS Level II code J1163, including how this code is used in clinical practice and payer interactions. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J1163 describes an injection of diltiazem hydrochloride, 0.5 mg. This code represents a single unit drug administration for the calcium channel blocker diltiazem given by injection.
Service type: Pharmacologic injection
Typical site of service: Outpatient infusion center, hospital outpatient department, emergency department, or physician office
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an emergency department or outpatient infusion clinic with acute supraventricular tachycardia (SVT) or rapid atrial fibrillation requiring rate control when oral therapy is not feasible or when intravenous titration is preferred. The patient is evaluated by emergency medicine or cardiology staff, including assessment of airway, breathing, circulation, continuous cardiac monitoring, baseline vital signs, and electrocardiography. Intravenous access is established and weight is confirmed to calculate dose. The clinician prepares a 0.5 mg vial of J1163 (diltiazem hydrochloride injection) and administers it per local protocol — commonly as an IV push or slow bolus — with cardiac monitoring for hypotension, bradycardia, or rhythm conversion. Post-administration, the patient is observed for response and adverse effects; additional therapies such as repeat dosing, continuous infusion, synchronized cardioversion, or admission may follow based on clinical response.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no special circumstances apply to the service. |
23 |